Aqueous gel containing kappa-carragheenan as gel-forming agent and, at least, 85% water

FIELD: veterinary science.

SUBSTANCE: the suggested aqueous gel for preventing and treating diseases of inferior urinary tract in cats and dogs includes: (a) efficient quantity of gel-forming agent being kappa-carragheenan, (b) efficient quantity of a substance that increases appetite in cats or dogs, and (c) at least, 85 weight% water. The innovation provides decreased concentration of mineral components in urine as a result of its increased production.

EFFECT: higher efficiency.

18 cl, 1 ex, 1 tbl

 

The technical field to which the invention relates.

Cats and dogs are prone to numerous diseases of the lower urinary tract. These include idiopathic disease of the urinary tract, crystalluria, bacterial cystitis, urolithiasis, idiopathic obstruction, occlusion of the ureter and other disease of the lower urinary tract (LUTD) is one of the most common disorders in cats. Urolithiasis, i.e. the formation of stones in the urinary tract, is a disease that detect both cats and dogs. Although the etiology of these diseases is not entirely clear, at least, one of the factors associated with disorders of this type, apparently, is a highly concentrated urine (i.e. high specific gravity of urine) or oversaturation of urine with mineral components. The decrease in the concentration of mineral components in the urine by increasing its production due to the increased water consumption can reduce the probability of formation of urinary crystals and stones, to promote the dissolution of some types of stones formed in the urinary tract, and the reduction of cases of feline LUTD. In addition, the increase in urine triggers an increase in the frequency of bladder emptying. More frequent emptying of the bladder reduces the risk of infectio the diseases of the urinary tract, of crystalluria and urolithiasis.

It was found that increasing appetite gel high humidity can significantly increase the absorption of water and the production of urine from these animals, like cats and dogs. As a result, this substance can be used for the prevention and/or treatment of diseases of the lower urinary tract, including crystalluria, urolithiasis, cystitis, idiopathic obstruction, blockage of the ureter and feline LUTD such animals as dogs or cats. In addition, this substance can improve the overall water absorbability and improve hydration in the case of diabetes, kidney disease, pregnancy, lactation, etc.

Summary of the invention

In accordance with the present invention serves gel, suitable for ingestion by dogs or cats, including

A. an effective amount of a gelling agent,

b. an effective amount of a substance that increases the appetite of dogs or cats, and

C. at least about 85% water.

According to another aspect of the invention provides for the use of the gel in the diet that meets the nutritional requirements of dogs or cats.

In accordance with another aspect of the invention provides gel for dogs or cats, the purpose of which is at least in the prevention of such diseases of the urinary tract of dogs or cats, as crystalluria, urolithiasis, cystitis, LUTD, idiopathic obstruction, a blockage of the ureter, etc. the Use of such substances on dogs or cats is particularly useful when the threat of disease of the urinary tract, i.e. in the predisposition of animals to the development of such diseases.

Another aspect of the present invention relates to a method of treatment of dogs or cats with a violation of the lower urinary tract, involving the use of animals with specified violations of the gel of the present invention.

Detailed description of the invention

Use gelatinising water causes increased total water consumption by dogs or cats, lowers the specific gravity of urine and provides increased urination compared to animals not receiving such a gel. Use gelatinising water is very effective not only in improving the overall water consumption and increased urination, but also due to the fact that provide a more favorable environment, eliminating the need to use a bowl for water and spray. In addition, there is an effective supply of animal water when traveling with permanent residence and back. Moreover, the pet owner is in the possibility of using a low-calorie food. This is especially useful for fat cats and dogs who have problems with overweight or obesity or conditions associated with overweight, such diseases as arthritis, diabetes, hypertension and cardiovascular disease. In addition, a very appetizing meal on the basis of water can improve water balance in animals receiving food with high protein content and/or requiring increased water consumption that occurs in cases of diabetes, lactation, training and growth.

Used gelling agent can be any substance that forms a gel in the presence of at least 85% of the mass. water, which may orally be used on dogs or cats. Examples of suitable gelling agents may serve as gelatin, carrageenan, agar, alginates, pectins, casatenovo gum, guar gum, Arabia gum, gum karaya, tragacanth gum, resin Tara (tara), Galanova gum, pullulan, curdlan, microcrystalline cellulose (MCC), carboxymethylcellulose (CMC), methylcellulose (MC), hypromellose (HPMC), chitosan, gum ghatti, beans Robinia, konjac flour, starch, etc.

Usually, addition of the basic substance used amplifier taste (flavor) to improve taste and neutralize any unpleasant taste in cats or dogs SV is related to the use of a gelling agent. Available materials of this type include animal usvoili, animal hydrolysates, internal animal organs (e.g. liver, lungs and heart), meat additives (for example, additives beef, lamb, pork, chicken and Turkey meat), seafood (e.g. fish, crabs, shrimp), dairy products (e.g. milk, cheese), yeast, peptides, amino acids, nucleotides, lipids, oils, artificial meat and/or fish odorants, maillard reactants, sugar, vegetable extracts, and other flavourings natural or artificial origin, which are attractive to cats or dogs.

A gelling agent is used in an amount sufficient to gel formation, a form-retaining, i.e. an object that can easily be eaten by a cat or dog. Under the shape retention means maintaining a solid structure, which can vary, like "jelly", while maintaining its integrity and not become fluid with the conversion into a liquid. Usually gelling agent is used in an amount of from about 0.05 to about 2 wt.% by weight of the gel, preferably from about 0.2 to about 1.5 wt.%.

A flavor enhancer used in an amount to provide increased appetite. Usually this amount is about 0.1-3 wt.%, preferably 0.3 to 0.5 wt.% based on the weight of the gel.

The amount of water in g the Le, usually constitutes at least about 85 wt.%, preferably at least 90-95% or more.

The gel may contain other components, such nutritional supplements, like vitamins and minerals, preservatives, coloring agents and active agents, including antibacterial agents, anti-inflammatory agents, antiparasitic, antioxidant, floral and/or herbal extracts, etc. and they all are used in effective amounts. Thus, the gel acts as a delivery system for additives and active ingredients.

The gels of the present invention can be easily obtained by standard methods. Such methods may include mixing all components in a container and stirring at ordinary or, if necessary, at elevated temperatures, the filling mixture container final form (gel form) and setting gel. For this purpose you can use the following components.

/tr>
Table
Component%
Water95,48
Kappa-carragan1,5
Chicken hydrolysate2,0
Brewer's yeast0,5
Sol0,3
Potassium sorbate0,2
FD&C Red No. 400,02
Only100,0

Processing stage

1. Mix ingredients in a heated container.

2. Heating the mixture to 160°F (320° (C) under stirring.

3. Keeping the mixture for 15 minutes at 160°F (320°).

4. Fill the mixture the desired shape.

5. Cooling gel and curing for 2 hours.

Below are examples of the present invention.

When using the gel of the present invention in the diet that meets the nutritional requirements of dogs and cats, may be a significant increase in water consumption and increased production of urine, as well as a significant decrease in its proportion. When using canned food, the total water consumption by dogs or cats may increase, at least about 20, preferably at least about 70 or 80%, and the production of urine to increase, at least about 20%, preferably about 90 or 100% of the mass. Specific gravity of urine can decrease, at least about 20, 30, or preferably, at least about 40%. When using dry feed, the total water consumption by cats or dogs can increase the I, at least about 15, 20, preferably at least about 25%, and the production of urine may increase, at least about 20, or preferably at least about 30 or 40%. Specific gravity of urine may decrease, at least about 10, 15, preferably at least approximately 20%.

Example 1

Used a crossover version of the study duration of eight weeks. Eight adult cats without limitation received deionized water and canned or dry food, with a complete and balanced nutritional composition. In addition to food, cat test group received the gel, the composition of which is specified in the table, whereas the control group of animals received no gel. By the end of the study, all cats received a combination of diet and gel. The following describes the conditions of the study.

Eight cats were divided into four groups of two in each group. In the first week, two groups of cats were given canned food, and two groups of dry food. The same diet was maintained in each of the groups and next week. However, one group of two cats receiving canned food, and one group of two cats receiving dry food (test group), gave the gel. The test substance was offered more than what their hours twice a day (8:30 to 9:30 and from 13:00 to 14:00). Other groups of animals (control group) gel is not received. In the third week of the diet remained, but the gel was not given. During the fourth week of the control and test group changed places. Now the group, the former control during the second week, got the gel, then as a group, the former test during the second week, did not get the gel. On the fifth week the animals were not receiving the gel, however, two groups of cats fed dry food, has now been canned food, and two groups receiving canned food, now received dry food. On the sixth week of the trial, one group from each diet was given the gel, and the other is not. On the seventh week of the test animals did not receive the gel. During the eighth week, the group not treated with the gel not the sixth week, was provided by the gel, and the gel was stopped in the group of animals treated him at the sixth week.

As a result of this methodology for the study, each group of two cats received dry food and canned food, receiving or not receiving the gel.

During the study, each cat was measured by water consumption from all sources (gel, water and food), urine output and specific gravity of urine. Other parameters measured in the study included weekly measurement of weight, daily measurement of food intake, urine pH is the quality of the chair.

In cats fed canned food and top gel, the total water consumption was increased by 70%; the production of urine was increased to 89 wt.%, and urinary specific gravity was decreased by 35% compared with the results obtained without the use of gel. All these changes are statistically significant. In cats fed dry food and the gel, the total water consumption increased by 20%; the production of urine was increased by 32%; and urinary specific gravity was decreased by 16%. All these changes are statistically significant (p< 0,01).

The use of gel had no effect on other measured parameters: body weight, food consumption, urine pH and the quality of the chair.

1. Water-based gel for the prevention or treatment of diseases of the lower urinary tract in cats or dogs, including

(a) an effective amount of a gelling agent,

(b) an effective amount of a substance that increases the appetite of cats or dogs, and

(c) at least 85 wt.% water.

2. Water-based gel according to claim 1, in which the gelling agent is a Kappa-carrageenan.

3. Water-based gel according to claim 1, containing at least 90 wt.% water.

4. Food for the prevention or treatment of diseases of the lower urinary tract in cats or dogs that meet the nutritional requirements for dogs and cats, including water-based gel according to claim 1.

5. Feed according to claim 4, in which the gelling Agay is t is a Kappa-carrageenan.

6. Feed according to claim 4, which contains at least 85 wt.% water.

7. Method of prevention of diseases of the lower urinary tract in cats or dogs, including feeding the cats or dogs aqueous gel according to claim 1.

8. The method according to claim 7, in which the gelling agent is a Kappa-carrageenan.

9. The method according to claim 7, in which water-based gel contains at least about 90 wt.% water.

10. The method according to claim 7, in which the condition of the lower urinary tract selected from the group consisting of kidney stones, crystalluria, cystitis, diseases of the lower urinary tract of cats and dogs and obstruct the ureter.

11. The method according to claim 10, in which the disease state is a urolithiasis.

12. The method of treatment of diseases of the lower urinary tract of cats or dogs, which consists in feeding the animals aqueous gel according to claim 1.

13. The method according to item 12, in which the gelling agent is a Kappa-carrageenan.

14. The method according to item 12, in which water-based gel contains at least 90 wt.% water.

15. The method according to item 12, in which the condition of the lower urinary tract selected from the group consisting of kidney stones, crystalluria, cystitis, idiopathic obstruction and blockage of the ureter.

16. The method according to item 15, in which the disease is a kidney stone.

17. Pic is b, facilitate increased total water consumption in need this to cats or dogs, which consists in feeding the animals aqueous gel according to claim 1.

18. The method according to 17, in which the cat or dog has diabetes or is in a state of lactation, training or growth.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method involves applying indirect lymphotropic therapy during the first three days before carrying out surgical intervention. Lidase is introduced into the first interdigital space from the injured hand backside 0.5-1.0 cm deep at a dose of 16-32 units diluted with 2.0 ml of 0.5% Novocain solution. Then, antibiotic solution is introduced without removing the needle 3-4 min later. The antibiotic solution is introduced twice a day in 12 h one after the other during the first 3 days with following forearm massage along the lymphatic ducts. Next antibiotic applications are done every morning as a part of lymphotropic therapy. The rest of antibiotic dose is introduced intramuscularly.

EFFECT: accelerated treatment course; increased T- and B-lymphocyte activity; reduced antibiotic consumption.

2 cl, 4 dwg

FIELD: cosmetic industry, phytotherapy.

SUBSTANCE: invention relates to a method for preparing cellular sap from microcarpous plume poppy above-ground part that involves milling the raw, twice extraction with a liquid consisting of 0.1% aqueous solution of NaCl with pH = 1-4 heated to temperature 80-90°C in the ratio of raw to the extractant volume = 1:0.5. Before squeezing out the primary sap is infused for 60-120 min in the constant stirring followed by squeezing the primary sac, then before squeezing the secondary sac is infused for 30 min followed by squeezing the secondary sap followed by combining the primary and secondary sap, sap preserving, its settling and filtration. Method provides preparing cellular sap with the enhanced content of biologically active substances.

EFFECT: improved preparing method.

2 tbl, 3 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a medicinal agent used in arresting syndrome of systemic inflammatory response. Agent comprises, mg: diphosphopyridine nucleotide, 0.3-100 and inosine, 40.0-1200. Proposed medicinal agent can comprise additionally inhibitor of angiotensin-converting enzyme, mainly, lisinopril, 2.5-100 and cardiac glycoside, mainly, digoxin, 0.07-0.3. The new medicinal agent possesses the capacity for arresting syndrome of systemic inflammatory response being independently of etiology of its rise, and allows obtaining the expressed and stable curative effect for short times.

EFFECT: improved and valuable properties of medicinal agent.

5 cl, 4 tbl, 4 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a medicinal agent used in arresting syndrome of systemic inflammatory response. Agent comprises, mg: diphosphopyridine nucleotide, 0.3-100 and inosine, 40.0-1200. Proposed medicinal agent can comprise additionally inhibitor of angiotensin-converting enzyme, mainly, lisinopril, 2.5-100 and cardiac glycoside, mainly, digoxin, 0.07-0.3. The new medicinal agent possesses the capacity for arresting syndrome of systemic inflammatory response being independently of etiology of its rise, and allows obtaining the expressed and stable curative effect for short times.

EFFECT: improved and valuable properties of medicinal agent.

5 cl, 4 tbl, 4 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes the stabilized pharmaceutical composition for topical treatment of infections chicken pox virus and herpes simplex virus of type 1 that comprises brivudine, i. e. (E)-5-(2-bromovinyl)-2'-deoxyuridine as an active substance and one or more metal oxide pigment in the concentration 10-50 wt.-% of the composition mass in common with pharmaceutically acceptable excipients. Metal oxide pigments are used as a photostabilizing agent of the composition. Invention provides enhancing the stability of composition.

EFFECT: improved properties of composition.

12 cl, 10 ex

FIELD: medicine.

SUBSTANCE: method involves taking 400 ml of patient blood before beginning treatment. Plasma is separated. 15 ml of auto plasma is taken and incubated with 9x106 MU of recombinant interferon α2b for 1 h at t 37°C and endolymphatically introduced to the patient at the first treatment day. The rest of the autoplasma is divided into two equal portions and saved in refrigerator. Next day, one autoplasma portion is taken and incubated with chemopreparations for 30 min at t 37°C in standard doses. Doxorubicin, Bleomycin, Vinbastin, Dacarbason are intravenously introduced as drop infusion. Said procedure of intravenous infusions of chemopreparations incubated with autoplasma is repeated at the ninth treatment day. 40 mg of prednisolone per day is introduced from the first to the tenth day. The treatment course is repeated when needed.

EFFECT: enhanced effectiveness of treatment.

1 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition used in treatment of tuberculosis by preparations based on protionamide. The pharmaceutical composition consists of a core comprising protionamide as an active substance, microcrystalline cellulose, calcium stearate, cellulose derivative, special additives, and envelope comprising cellulose derivative, dye and accessory substance. Hydroxypropylcellulose is used as a derivative of cellulose, and calcium hydrophosphate dihydrate and croscarmelose sodium are used as special additives, and copolymer of vinylpyrrolidone with vinyl acetate taken in the ratio = 6:4 is used as accessory substance in envelope. Invention provides enhancing stability at storage and rapid release of active substance in digestive tract.

EFFECT: improved and valuable pharmaceutical properties of pharmaceutical composition.

2 tbl

FIELD: medicine.

SUBSTANCE: method involves administering Nateglynid and Glytazon in pharmaceutically permissible carrier. The combination is optionally administered as combined preparation or pharmaceutical composition. The pharmaceutical composition (the second version) has Nateglynid and Methformin as the second anti-diabetic agent enclosed into the pharmaceutical carrier.

EFFECT: enhanced effectiveness of synergetic preparations action upon diabetes II; prolonged therapeutic drug action time; postponed insulin administration.

13 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves administering Nateglynid and Glytazon in pharmaceutically permissible carrier. The combination is optionally administered as combined preparation or pharmaceutical composition. The pharmaceutical composition (the second version) has Nateglynid and Methformin as the second anti-diabetic agent enclosed into the pharmaceutical carrier.

EFFECT: enhanced effectiveness of synergetic preparations action upon diabetes II; prolonged therapeutic drug action time; postponed insulin administration.

13 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves making lumbar puncture in postoperative period. Subarachnoid space is catheterized and 5 ml of liquor is taken and incubated with 5 mg of Nimustin for 30 min at 38°C and introduced through the catheter into the subarachnoid space.

EFFECT: enhanced effectiveness of treatment; reduced toxic effect.

FIELD: medicine, in particular experimental biology.

SUBSTANCE: invention relates to method for prophylaxis and treatment of systemic amyloidosis and nephropathic form thereof, induced in experimental animal. In this purpose 10 % mildronate solution is hypodermically administrated to animals every second day in dose of 50 mg/kg during last 14 days of experiment.

EFFECT: effective method for disease treatment due to simultaneous action on different component of pathogenesis, namely amyloid mass formation in kidney.

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivative of triazaspiro[5.5]undecane of the formula (I): wherein R1 means compound of the formula (1): or (2): wherein G represents a bond, (C1-C4)-alkylene, (C2-C4)-alkenylene or -CO-; ring A represents: (1) C5-10-membered mono- or bicarbocyclic ring or (2) 5-10-membered mono- or bicyclic heterocycle comprising 1-2 nitrogen atoms and/or 1-2 oxygen atoms; substitute R6 means the following values: (1) (C1-C4)-alkyl, (2) halogen atom, (3) nitrile group, (4) trifluoromethyl group and others; R2 represents: (1) (C1-C4)-alkyl, (2) (C2-C4)alkynyl or (3) (C1-C4)-alkyl substituted with a substitute represented in claim 1 of the invention claim; each R3 and R4 represents independently: (1) hydrogen atom, (2) (C1-C4)-alkyl or (3) (C1-C4)-alkyl substituted with 1-2 substituted taken among: (a) Cyc 2 and (b) hydroxy-group (wherein Cyc 2 represents (1) C5-6-membered monocarbocyclic ring or (2) 5-6-membered monocyclic heterocycle comprising 1-2 nitrogen atoms and/or one oxygen atom), or R3 and R4 form in common group of the formula: wherein R26 represents (C1-C4)-alkyl or Cyc 2; R5 represents hydrogen atom or (C1-C4)-alkyl, its quaternary ammonium salt, its N-oxide or its nontoxic salt. Also, invention relates to pharmaceutical composition inhibiting HIV, regulator of chemokine/chemokine receptor and agent used in treatment and prophylaxis of some diseases, such as inflammatory diseases, asthma, atopic dermatitis, nettle rash, allergic diseases, nephritis, hepatitis, arthritis and other diseases that comprise as an active component above described compound of the formula (I) or its quaternary ammonium salt, its N-oxide or its nontoxic salt. Also, invention relates to (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane or its pharmaceutically acceptable salt and pharmaceutical composition based on thereof, and to (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane hydrochloride and pharmaceutical composition based on thereof.

EFFECT: valuable medicinal properties of derivative and composition.

16 cl, 32 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new derivatives of triazaspiro[5,5]undecane of the formula (I):

wherein values of radicals R1-R5 are given in the invention claim, ort o their quaternary ammonium salts, N-oxides or nontoxic salts. Proposed compounds possess inhibitory and regulating activity with respect to chemokine/chemokine receptors and can be useful in prophylaxis and treatment of different inflammatory diseases, such as asthma, atopic dermatitis, nettle rash, allergic diseases, nephritis, hepatitis, arthritis or proliferative arthritis and other similar diseases. Also, invention relates to pharmaceutical compositions based on compounds of the formula (I).

EFFECT: improved control method, valuable medicinal properties of compounds.

9 cl, 5 sch, 36 tbl, 70 ex

FIELD: medicine, nephrology.

SUBSTANCE: the present innovation deals with introducing mildronate per 0.25 g 4 times daily about 30 min before meals for 3 wk, and then - per 0.25 g thrice daily about 30 min before meals for 4 wk at the background of daily intake of dipiridamol at the dosage of 200 mg/d. If necessary, therapeutic course should be repeated in 6 mo. The innovation improves endothelial function that leads to suppressed inflammatory process in kidneys and their improved functional capacity.

EFFECT: higher efficiency of therapy.

1 ex, 1 tbl

FIELD: organic chemistry, pharmacy, biochemistry.

SUBSTANCE: invention relates to new substituted 2H-pyrano[2,3-c] of the general formula (1) eliciting ability to inhibit activity of protein kinase. In the general formula (1) X represents oxygen atom or group NR3; R1 represents group -C(O)R4, optionally substituted and optionally condensed azaheterocycle; R2 represents optionally substituted hydroxyl group or optionally substituted amino-group; R3 represents hydrogen atom or inert substitute meaning optionally substituted low- or non-reactive radical including such as (C1-C7)-alkyl, (C2-C7)-alkenyl, (C2-C7)-alkynyl, (C1-C7)-alkoxy-group, (C7-C12)-aralkyl, heterocyclylalkyl, (C7-C12)-alkaryl, (C3-C10)-cycloalkyl, (C3-C10)-cycloalkenyl, phenyl, aryl, (C2-C12)-alkoxyalkyl, (C2-C10)-alkylsulfinyl, (C2-C10)-alkylsulfonyl, -(CH2)-O-(C1-C7-alkyl), -(CH2)m-N(C1-C7-alkyl)n, aryloxyalkyl, heterocyclyl wherein m and n have value from 1 to 7; R4 represents optionally substituted amino-group or hydrogenated optionally substituted azaheterocycle. Also, invention relates to combinatory and focused libraries consisting of compounds of the present invention and designated for the search of compound-hits and compound-leaders prepared by screening of these libraries for using in preparing medicinal agents.

EFFECT: valuable medicinal properties of compounds.

8 cl, 2 tbl, 6 ex

FIELD: organic chemistry, vitamins, medicine, pharmacy.

SUBSTANCE: invention relates to a new compound of the formula (I): wherein X means hydrogen atom or hydroxy group; R1 and R2 that can be similar or different mean hydrogen atom, (C1-C4)-alkyl; R3 means hydrogen atom, methyl group, fluorine or chlorine atom. Also, invention relates to its esters able to hydrolysis in vivo in combination with pharmaceutically acceptable acids. Also, invention relates to a pharmaceutical composition eliciting the inhibitory activity with respect to proliferation and promoting differentiation of cells and comprising the effective dose of compound of the formula (I) in common with pharmaceutically acceptable carriers and/or excipients. Also, invention relates to applying compound of the formula (I) for preparing a medicine used in treatment and prophylaxis of disease characterizing by abnormal differentiation of cells and/or proliferation of cells.

EFFECT: valuable medicinal properties of compounds.

13 cl, 3 sch, 3 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: method involves applying dietotherapy of zoosterol as 0.5% of aqueous solution in the amount of 100-200 ml in the morning 30 min before taking meals at a daily dose of 0.5-1.0 g in 21 days long course.

EFFECT: enhanced effectiveness in correcting metabolism disorders.

1 tbl

FIELD: organic chemistry, medicine, chemical-pharmaceutical industry, pharmacology, pharmacy.

SUBSTANCE: invention relates to a medicinal agent used for prophylaxis and treatment of diseases and disorders associated with dysfunction of benzodiazepine receptors. This medicinal agent comprises compound of the formula (I)

. Compound of the formula (I) elicits high cardioprotective, neurotrophic, renoprotective activity and enhanced bioavailability.

EFFECT: valuable medicinal properties of compounds.

5 cl, 1 tbl, 1 ex

Drug // 2234331
The invention relates to the field of pharmaceuticals, namely, to medicines, and can be used to adjust the chemical composition of food, for example, metabolic disorders in patients with chronic renal failure

The invention relates to new compounds of formula I and Ia in all their stereoisomeric forms or their mixtures in all ratios, and their pharmaceutically acceptable salts, which has antagonistic activity against vitronectin receptor

FIELD: organic chemistry, medicine, pharmacology.

SUBSTANCE: invention relates to using substituted derivative of 6-dimethylaminomethyl-1-phenylcyclohexane of the formula (I) for preparing a medicinal agent designated for treatment of more frequent urge for urination and enuresis, respectively. Proposed medicinal agent possesses less adverse effects and/or analgesic effects.

EFFECT: improved and valuable medicinal properties of compounds.

12 cl, 2 tbl, 3 ex

Up!